Carbon dioxide intranasal - Soleno Therapeutics

Drug Profile

Carbon dioxide intranasal - Soleno Therapeutics

Alternative Names: Serenz; Serenz Allergy Relief

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Capnia
  • Developer Soleno Therapeutics
  • Class Inorganic carbon compounds; Oxides
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis; Cluster headache; Trigeminal neuralgia

Most Recent Events

  • 12 Apr 2017 Capnia terminates a phase II trial in Cluster headache in USA (Intranasal) (NCT02381795)
  • 13 May 2016 9195736 - added trial Phase II TN description
  • 21 Dec 2015 Carbon dioxide intranasal - Capnia receives Orphan Drug status for Trigeminal neuralgia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top